메뉴 건너뛰기




Volumn 24, Issue 25, 2006, Pages 5320-5326

Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene®) in healthy adults

Author keywords

Hepatitis B vaccine; Hepavax Gene ; Thiomersal free

Indexed keywords

HEPAVAX GENE; RECOMBINANT HEPATITIS B VACCINE; THIOMERSAL; UNCLASSIFIED DRUG;

EID: 33744922905     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.018     Document Type: Article
Times cited : (20)

References (17)
  • 1
    • 33744899135 scopus 로고    scopus 로고
    • World Health Organization, fact sheet no. 204: hepatitis B. Revised October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html [accessed 18 May 2005].
  • 2
    • 0029993966 scopus 로고    scopus 로고
    • Progress towards the comprehensive control of hepatitis B. Introduction
    • Zuckerman A.J. Progress towards the comprehensive control of hepatitis B. Introduction. Gut 38 (1996) S1
    • (1996) Gut , vol.38
    • Zuckerman, A.J.1
  • 3
    • 0032434467 scopus 로고    scopus 로고
    • Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board
    • Grob P., Hallauer J., Kane M., McCloy E., Meheus A., Roure C., et al. Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board. Vaccine 16 Suppl. (1998) S1-S2
    • (1998) Vaccine , vol.16 , Issue.SUPPL
    • Grob, P.1    Hallauer, J.2    Kane, M.3    McCloy, E.4    Meheus, A.5    Roure, C.6
  • 4
    • 0037383496 scopus 로고    scopus 로고
    • Geneva, Switzerland; 13-14 September 2002 Consensus statement [short version]
    • EASL Jury. EASL international consensus conference on hepatitis B. Geneva, Switzerland; 13-14 September 2002. J Hepatol 38 (2003) 533-540 Consensus statement [short version]
    • (2003) J Hepatol , vol.38 , pp. 533-540
    • EASL Jury1
  • 5
    • 27644530137 scopus 로고    scopus 로고
    • Recombinant hepatitis B vaccines: disease characterization and vaccine production
    • Gellissen G. (Ed), Wiley-VCH, Weinheim
    • Brocke P., Schaefer S., Melber K., Jenzelewski V., Müller F., Dahlems U., et al. Recombinant hepatitis B vaccines: disease characterization and vaccine production. In: Gellissen G. (Ed). Production of recombinant proteins (2005), Wiley-VCH, Weinheim 319-359
    • (2005) Production of recombinant proteins , pp. 319-359
    • Brocke, P.1    Schaefer, S.2    Melber, K.3    Jenzelewski, V.4    Müller, F.5    Dahlems, U.6
  • 6
    • 0030433396 scopus 로고    scopus 로고
    • Phase III clinical trial for immunogenicity and safety of a recombinant hepatitis B virus vaccine (HG-II) in the newborn
    • Cho Y.K., Jung Y.S., Yi G.W., Kim Y.O., Choi M.B., Shin S.K., et al. Phase III clinical trial for immunogenicity and safety of a recombinant hepatitis B virus vaccine (HG-II) in the newborn. Korean J Clin Pharmacol Ther 4 (1996) 197-205
    • (1996) Korean J Clin Pharmacol Ther , vol.4 , pp. 197-205
    • Cho, Y.K.1    Jung, Y.S.2    Yi, G.W.3    Kim, Y.O.4    Choi, M.B.5    Shin, S.K.6
  • 7
    • 0037086485 scopus 로고    scopus 로고
    • Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years
    • Hieu N.T., Kim K.H., Janowicz Z., and Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 20 (2002) 1803-1808
    • (2002) Vaccine , vol.20 , pp. 1803-1808
    • Hieu, N.T.1    Kim, K.H.2    Janowicz, Z.3    Timmermans, I.4
  • 8
    • 33744927206 scopus 로고    scopus 로고
    • Janowicz ZA, Timmermans ITF, Ahn SJ. Hepavax-Gene, a recombinant hepatitis B vaccine: safety and immunogenicity in healthy adults. In: Proceedings of the 10th international congress on infectious diseases [poster presentation].
  • 9
    • 33744946601 scopus 로고    scopus 로고
    • Nguyen TH, Kyung-Ho K, Janowicz Z, Timmermans I. Safety and immunogenicity of Hepavax-Gene, a recombinant hepatitis B vaccine, during the first six years of life, following vaccination at 0, 1 and 2 months. In: Proceedings of the 4th European conference on viral disease [poster presentation].
  • 10
    • 33744920375 scopus 로고    scopus 로고
    • Timmermans ITF, Choi YJ, Kim KH. Summary of clinical experience with recombinant hepatitis B vaccine administered with the 0-1-6 months dosage schedule. In: Proceedings of the 10th international congress on infectious diseases [poster presentation].
  • 11
    • 33744941898 scopus 로고    scopus 로고
    • Berna Biotech Ltd. Data on file.
  • 12
    • 0037159545 scopus 로고    scopus 로고
    • Global advisory committee on vaccine safety, 20-21 June 2002
    • World Health Organization. Global advisory committee on vaccine safety, 20-21 June 2002. Wkly Epidemiol Rec 77 (2002) 389-394
    • (2002) Wkly Epidemiol Rec , vol.77 , pp. 389-394
    • World Health Organization1
  • 13
    • 33744945085 scopus 로고    scopus 로고
    • World Health Organization. Statement on thiomersal. Issued August 2003. Available at: www.who.int/vaccine_safety/topics/thiomersal/statement200308/en/ [accessed 5 August 2004].
  • 14
    • 0024435696 scopus 로고
    • Vaccination against hepatitis B: comparison of three different vaccination schedules
    • Jilg W., Schmidt M., and Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 160 (1989) 766-769
    • (1989) J Infect Dis , vol.160 , pp. 766-769
    • Jilg, W.1    Schmidt, M.2    Deinhardt, F.3
  • 15
    • 0001566476 scopus 로고    scopus 로고
    • Are booster immunisation needed for lifelong hepatitis B immunity
    • European Consensus Group on hepatitis B immunity
    • European Consensus Group on hepatitis B immunity. Are booster immunisation needed for lifelong hepatitis B immunity. Lancet 355 (2000) 561-565
    • (2000) Lancet , vol.355 , pp. 561-565
  • 16
    • 0038826672 scopus 로고    scopus 로고
    • Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients
    • Gunson R.N., Shouval D., Roggendorf M., Zaajer H., Nicholas H., Holzmann H., et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 27 (2003) 213-230
    • (2003) J Clin Virol , vol.27 , pp. 213-230
    • Gunson, R.N.1    Shouval, D.2    Roggendorf, M.3    Zaajer, H.4    Nicholas, H.5    Holzmann, H.6
  • 17
    • 0001660020 scopus 로고    scopus 로고
    • Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2002
    • STIKO. Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2002. Epid Bull RKI 28 (2002) 227-242
    • (2002) Epid Bull RKI , vol.28 , pp. 227-242
    • STIKO1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.